Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Contineum Therapeutics, Inc.

NASDAQ: CTNM · Life Sciences · 3 alerts · CIK 1855175

Share price
$9.67Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Contineum Therapeutics, Inc. filings on SEC EDGAR ↗

4:07 PM ET 8-K
Clinical Trial Data

Contineum Therapeutics Clinical Trial Data

Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for major depressive disorder did not meet its primary efficacy endpoint of improvement in the MADRS total score. The drug candidate, which is being developed under a global license agreement with Johnson & Johnson, was well-tolerated with no new safety signals. Johnson & Johnson is currently evaluating the full data set, including exploratory endpoints, to determine the next steps for the program.

Counterparty
Johnson & Johnson

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.